Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$601.71 USD
+2.46 (0.41%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $601.55 -0.16 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$601.71 USD
+2.46 (0.41%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $601.55 -0.16 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher (TMO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Integer (ITGR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should ISRG Stock Be Part of Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's third-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
Danaher to Benefit From Business Strength Amid Headwinds
by Zacks Equity Research
DHR stands to benefit from strength in the clinical diagnostics business, Abcam buyout and shareholder-friendly policies. Softness in the Instrument unit remains a concern.
MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests
by Zacks Equity Research
Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
by Zacks Equity Research
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Should You Continue to Hold TMO Stock in Your Portfolio?
by Zacks Equity Research
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
by Zacks Equity Research
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
by Zacks Equity Research
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
by Zacks Equity Research
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
The Zacks Analyst Blog Highlights JPMorgan Chase, Thermo Fisher, Arista Networks, United Homes Group and GSI
by Zacks Equity Research
JPMorgan Chase, Thermo Fisher, Arista Networks, United Homes Group and GSI are included in this Analyst Blog.
Top Research Reports for JPMorgan, Thermo Fisher & Arista Networks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Thermo Fisher Scientific Inc. (TMO) and Arista Networks, Inc. (ANET), as well as two micro-cap stocks United Homes Group, Inc. (UHG) and GSI Technology, Inc. (GSIT).
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Top Analyst Reports for Apple, NVIDIA & Coca-Cola
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and The Coca-Cola Company (KO), as well as two micro-cap stocks Star Group, L.P. (SGU) and Aware, Inc. (AWRE).
Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI
by Zacks Equity Research
Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
by Zacks Equity Research
Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma
The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Micron Technology, KLA and Moving iMage Technologies
by Zacks Equity Research
Thermo Fisher Scientific, Micron Technology, KLA and Moving iMage Technologies are included in this Analyst Blog.
Top Research Reports for Thermo Fisher Scientific, Micron Technology & KLA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), Micron Technology, Inc. (MU) and KLA Corporation (KLAC), as well a micro-cap stock Moving iMage Technologies, Inc. (MITQ).
Company News for Jul 25, 2024
by Zacks Equity Research
Companies in the News Are: NEE, TMO, GD, LW.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.